Re trial. My memory was the anticipated path would be:
- likely recruit 2x patients per month
- aiming for 10 patients
- split 7 internal Lymphoma, 3 skin lymphoma
Length of time trial to run for was not, as far as I could remember, explicitly stated. What was stated was that average length of response to "current standard of care treatment" was 4 months. some respond for longer, some shorter.
And a follow up comment was made that, due to average length of response to current treatment being 4 months, that (to paraphrase), it would not take a lengthy trial to determine whether the drug was working
Implies, to me:
- if all goes to plan there will be 10 patients recruited from Oct, 2021. Through to Feb 2022.
- If last patients recruited Feb 2022. Six months after Feb 2022 is August 2022. Add on time to analyse data.
It will take a while before there is meaningful data that could be shared. At most out-rageously optimistic - End Q1 2022. Slighlty more realistic but still extremely optimistic - end Q2 2022. Starting to feel like it is realistic optimism - end Q3 2022.
- Forums
- ASX - By Stock
- PTX
- ptx-100 presentation
ptx-100 presentation, page-4
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
|
|||||
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $37.85M |
Open | High | Low | Value | Volume |
4.9¢ | 5.0¢ | 4.6¢ | $54.50K | 1.134M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 108715 | 4.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 189091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 108715 | 0.047 |
3 | 249374 | 0.046 |
3 | 220000 | 0.045 |
2 | 106598 | 0.043 |
4 | 352851 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 189091 | 2 |
0.050 | 348310 | 3 |
0.052 | 19230 | 1 |
0.054 | 51093 | 1 |
0.055 | 325000 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
PTX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online